Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with unmet medical need. Co.'s clinical-stage product candidates include: rilonacept, which is a protein cytokine trap for inhibiting interleukin-1 alpha and interleukin-1 beta; mavrilimumab, which is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor; and KPL-716, which is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31 and oncostatin M by targeting their common receptor subunit, oncostatin M receptor beta. The KNSA stock yearly return is shown above.
The yearly return on the KNSA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KNSA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|